# Sermorelin, CJC-1295 and ipamorelin compared

> Growth outcomes compared | High Peak Peptides — Compare sermorelin, CJC-1295 and ipamorelin at High Peak Peptides by childhood height, adult hormones, animal findings and patient recovery.

Childhood height, a persistent blood response and an earlier meal are different ambitions. There is no common clinical contest hidden in these studies.

## Study outcomes by population

I’d resist a league table with a single winner. The studies use different populations and ask different questions. This comparison gives each result its own row, so an adult hormone measurement cannot quietly acquire the meaning of a childhood height gain.

| Compound | Population | Measured result |
| --- | --- | --- |
| Sermorelin | Prepubertal children with GH deficiency | [Faster first-year height growth](https://pubmed.ncbi.nlm.nih.gov/8772599/). |
| CJC-1295 DAC | Healthy adults | [GH and IGF-1 elevations lasting days](https://pubmed.ncbi.nlm.nih.gov/16352683/). |
| Ipamorelin | Adult female rats | [Increased longitudinal bone growth](https://pubmed.ncbi.nlm.nih.gov/10373343/). |
| Ipamorelin | Ferrets given cisplatin | [Reduced later weight loss, without reduced vomiting](https://pubmed.ncbi.nlm.nih.gov/39043357/). |
| Ipamorelin | Adults undergoing bowel resection | [Primary recovery endpoint missed](https://pubmed.ncbi.nlm.nih.gov/25331030/). |

The height result is the most concrete human growth outcome here. The animal findings broaden the biological possibilities. The missed patient-trial endpoint gives an equally concrete reason to remain cautious.

## Receptors and duration

Sermorelin and CJC-1295 stimulate the GHRH receptor on the pituitary. Sermorelin closely copies the active hormone fragment; CJC-1295 carries stabilising changes and, in its DAC form, an [albumin attachment that extends activity](https://pubmed.ncbi.nlm.nih.gov/15817669/).

Ipamorelin stimulates the ghrelin receptor. Its [human intravenous study](https://pubmed.ncbi.nlm.nih.gov/10496658/) found a brief GH pulse peaking at about 40 minutes, with an approximately 2-hour terminal half-life. CJC-1295 DAC had an [estimated half-life of 5.8–8.1 days](https://pubmed.ncbi.nlm.nih.gov/16352683/) in healthy adults.

Those duration figures describe the compounds’ disappearance from blood. They do not rank how well people slept, functioned or recovered. I’d choose a patient outcome before choosing a duration to admire.

## Combinations and related molecules

Different receptors provide a reason to investigate combining a GHRH analogue with a ghrelin-receptor agonist. Separate single-compound studies, however, supply no controlled human outcome result for CJC-1295 plus ipamorelin. The claim about the pair needs evidence about the pair.

Tesamorelin supplies a useful example of why the name of the tested compound matters. The [older-adult cognition trial](https://pubmed.ncbi.nlm.nih.gov/22869065/) used tesamorelin. Its cognition and body-fat findings cannot establish the same effects for sermorelin or CJC-1295.

I’d let the smaller, precise achievement stand. Childhood sermorelin growth, prolonged CJC-1295 activity and the separate ipamorelin findings are already worth examining. The [compound essays](/sermorelin) contain the qualifications that a crowded comparison can easily lose.

---

An independent field notebook for the GH axis—where every peak keeps its time stamp, every claim keeps its source, and no curve becomes medical advice.